10-Q: Fulcrum Therapeutics Announces Strategic Collaboration with Sanofi for FSHD Drug Losmapimod

Fulcrum Therapeutics has entered into a significant collaboration and license agreement with Sanofi, granting exclusive rights to commercialize losmapimod, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD), outside the United States.

Summary

• Fulcrum Therapeutics has entered into a collaboration and license agreement with Sanofi, granting Sanofi exclusive rights to commercialize losmapimod, an oral small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), outside of the United States.
• Fulcrum will continue to conduct the ongoing Phase 3 clinical trial for losmapimod (REACH) and will share global development costs equally with Sanofi.
• Sanofi made an upfront payment of $80.0 million to Fulcrum in Q2 2024.
• Fulcrum is eligible to receive up to $975.0 million in regulatory and sales-based milestones.
• Sanofi will pay Fulcrum tiered royalties ranging from low-teens to mid-twenties percent on annual net sales of losmapimod outside the United States.
• Fulcrum retains full U.S. commercialization rights for losmapimod and will supply Sanofi
• s clinical and commercial supply requirements until Sanofi elects to take over manufacturing responsibilities.', 'Fulcrum reported net income of $28.5 million for the six months ended June 30, 2024, primarily due to the $80.0 million upfront payment from Sanofi, compared to a net loss of $48.6 million for the same period in 2023.', 'As of June 30, 2024, Fulcrum had $273.8 million in cash, cash equivalents, and marketable securities, which is estimated to fund operations into 2027.'

Sentiment

Score: 9

Explanation: The document reflects a highly positive sentiment due to the significant upfront payment, potential milestone payments, royalty structure, and the strategic partnership with a major pharmaceutical company, indicating strong confidence in the potential of losmapimod.

Positives

• The collaboration with Sanofi provides significant upfront funding of $80.0 million and potential future milestone payments up to $975.0 million.
• The agreement validates the potential of losmapimod as a treatment for FSHD.
• Sanofi
• s global commercial infrastructure and expertise will help maximize the reach of losmapimod outside the U.S.', 'Fulcrum retains full U.S. commercialization rights for losmapimod, allowing it to capture significant value in a major market.', 'The collaboration allows Fulcrum to share future global development costs for losmapimod with Sanofi, reducing financial risk.', 'Fulcrum's existing cash, cash equivalents, and marketable securities are estimated to fund operations into 2027.'

Negatives

• Fulcrum has incurred significant losses since inception and expects to continue to incur losses for the foreseeable future, excluding potential milestone payments from Sanofi.
• Clinical drug development is lengthy, expensive, and uncertain, with a high risk of failure.
• The FDA placed a full clinical hold on the IND application for pociredir in SCD in February 2023, which was lifted in August 2023, but highlights regulatory risks.
• Enrollment in the Phase 1b clinical trial for pociredir in SCD is challenging due to revised inclusion and exclusion criteria.
• Fulcrum faces substantial competition from other pharmaceutical and biotechnology companies developing treatments for rare diseases.

Risks

• Fulcrum may never achieve or maintain profitability.
• Fulcrum will need substantial additional funding to support operations and may be forced to delay, reduce, or eliminate product development programs if unable to raise capital.
• Clinical trials may fail to demonstrate safety and efficacy, and regulatory approvals may be delayed or not obtained.
• The market opportunity for Fulcrum
• s product candidates may be smaller than estimated.', 'Fulcrum relies on third parties for manufacturing and clinical trials, which may not perform satisfactorily.', 'Fulcrum may not be able to establish sales, marketing, and distribution capabilities or enter into favorable agreements with third parties for commercialization.', 'Fulcrum may not be able to obtain, maintain, enforce, and protect patent protection for its technology and product candidates.', 'Fulcrum may face legal proceedings related to intellectual property or product liability.', 'Changes in tax laws or healthcare regulations could adversely affect Fulcrum's business.', 'Fulcrum's ability to use net operating losses and research and development tax credits may be limited.', 'Adverse developments in the financial services industry could impact Fulcrum's access to funding.', 'The ongoing conflict in Israel and Gaza could impact clinical trials or the supply chain.'

Future Outlook

Fulcrum expects operating losses to continue into the foreseeable future as it expands its research and development efforts. The company believes that its existing cash, cash equivalents, and marketable securities as of June 30, 2024, will be sufficient to fund operations into 2027. Fulcrum expects to report topline data from the REACH trial by the end of October 2024 and to provide clinical data from the pociredir trial in 2025.

Management Comments

• This deal aligns with our core strategy, allowing Fulcrum to remain focused on preparations for commercialization of losmapimod in the U.S., while leveraging Sanofis exceptional global commercial capabilities and established infrastructure in key markets around the world.
• We are excited about the potential to provide the first approved treatment for FSHD patients, and we look forward to working with Sanofi to bring losmapimod to patients globally.

Industry Context

This announcement positions Fulcrum as a key player in the FSHD treatment landscape, potentially the first to market with an approved therapy. The collaboration with Sanofi, a major player in rare diseases, strengthens Fulcrums position and provides access to a global commercialization infrastructure. The deal also highlights the growing interest and investment in developing treatments for rare neuromuscular diseases.

Comparison to Industry Standards

• The upfront payment of $80.0 million and potential milestone payments of up to $975.0 million are significant and comparable to other licensing deals in the rare disease space.
• For example, in 2023, Amgen acquired Horizon Therapeutics for $27.8 billion, gaining access to a portfolio of rare disease drugs, including Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout.
• In 2022, Pfizer acquired Global Blood Therapeutics, a company focused on sickle cell disease, for $5.4 billion.
• These deals demonstrate the high value placed on companies with promising rare disease assets.
• Fulcrums collaboration with Sanofi is also in line with the industry trend of smaller biotech companies partnering with larger pharmaceutical companies to leverage their commercialization expertise and global reach.
• For example, in 2023, Alnylam Pharmaceuticals entered into a collaboration with Roche to develop and commercialize zilebesiran, an investigational RNAi therapeutic for hypertension, with Alnylam receiving an upfront payment of $310 million and being eligible for up to $2.8 billion in milestone payments.
• Compared to industry standards, the Fulcrum-Sanofi deal is significant for a pre-commercial asset, reflecting the potential of losmapimod and the unmet need in FSHD.

Legal Proceedings

• On April 28, 2023, a class action complaint was filed in the United States District Court for the District of New Jersey against the Company and current and former officers (the Securities Action).
• On May 19, 2023, the Securities Action was transferred to the United States District Court for the District of Massachusetts, captioned Celano v. Fulcrum Therapeutics, Inc., et al., Case No. 1:23-cv-11125-IT.
• On July 31, 2023, the court appointed a lead plaintiff, who filed an amended complaint on September 29, 2023.
• The Securities Action alleges violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder against all defendants and control person violations of Section 20(a) against the individuals, related to the Companys February 2023 announcement that the U.S. Food and Drug Administration issued a clinical hold regarding the investigational new drug application for pociredir for the potential treatment of sickle cell disease.
• The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information related to the clinical hold and seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between March 3, 2022, and March 8, 2023, as well as attorneys fees and costs.
• On November 28, 2023, all defendants filed a motion to dismiss the Securities Action.
• Briefing was completed on the motion in February 2024, and the motion is currently pending.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased funding, validation of technology, and potential for future revenue streams. However, potential dilution if additional capital is raised.
• Employees: Potential positive impact due to increased resources for research and development and potential for company growth. However, potential negative impact if restructuring or cost-cutting measures are implemented.
• Customers: Potential positive impact due to the potential for a new treatment for FSHD, a disease with high unmet medical need.
• Suppliers: Potential positive impact due to increased demand for goods and services related to the development and commercialization of losmapimod.
• Creditors: Potential positive impact due to improved financial stability and potential for future revenue streams.

Next Steps

• Continue the Phase 3 REACH trial for losmapimod, with topline data expected by the end of October 2024.
• Continue the Phase 1b clinical trial for pociredir, with a focus on enrolling subjects with higher disease severity.
• Provide clinical data from the pociredir trial in 2025.
• Work with Sanofi to prepare for potential regulatory submissions and commercialization of losmapimod outside the U.S.
• Continue research and development efforts to identify and validate drug targets for other genetically-defined rare diseases.

Key Dates

Keywords

FSHD, losmapimod, pociredir, rare disease, clinical trials, biopharmaceutical, drug development, collaboration, licensing, commercialization, Sanofi, MyoKardia, GSK, CAMP4, FDA, Phase 3, REACH, sickle cell disease, facioscapulohumeral muscular dystrophy